|Dr. Stephanie Laine Morley D.V.M., DVM||Pres & Chief Medical Officer||263.37k||N/A||1975|
|Mr. Bruk Herbst||Chief Commercial Officer||N/A||N/A||1969|
|Mr. Robert Cohen||CEO & Director||N/A||N/A||1958|
|Ms. Ann Marie Cotter CPA||CFO & Sec.||N/A||N/A||1970|
|Mr. Michael Schilk||VP of Sales||N/A||N/A||N/A|
|Mr. David Eaton||VP of Marketing||N/A||N/A||N/A|
|Dr. William Carpenter MacArthur||Consultant||N/A||N/A||1963|
|Mr. Robert W. DiMarzo||Consultant||N/A||N/A||1957|
Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Zomedica Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.